Compare · A vs ALMR
A vs ALMR
Side-by-side comparison of Agilent Technologies Inc. (A) and Alamar Biosciences Inc. (ALMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and ALMR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $42.53B, about 19.9x ALMR ($2.14B).
- A has been more active in the news (9 items in the past 4 weeks vs 4 for ALMR).
- A has more recent analyst coverage (25 ratings vs 5 for ALMR).
- Company
- Agilent Technologies Inc.
- Alamar Biosciences Inc.
- Price
- -
- -
- Market cap
- $42.53B
- $2.14B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2026
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 5
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors
- Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System
- SEC Form S-4 filed by Agilent Technologies Inc.
- SEC Form S-3ASR filed by Agilent Technologies Inc.
- SEC Form 10-Q filed by Agilent Technologies Inc.
- Agilent Introduces the Cary 635 FTIR Spectrometer
- Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
- Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
Latest ALMR
- Director Ragusa Robert P was granted 5,686 shares (SEC Form 4)
- SEC Form 3 filed by new insider Ragusa Robert P
- Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 8-K filed by Alamar Biosciences Inc.
- SEC Form SCHEDULE 13G filed by Alamar Biosciences Inc.
- SEC Form 10-Q filed by Alamar Biosciences Inc.
- Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
- Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
- Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome